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Organic nitrates, such as nitroglycerin (GTN) have been
used since the 19th century for the treatment of angina
pectoris, ischemia and hypertension. Like S-nitrosothiols,
organic nitrates are NO-generating compounds that are
vasoactive via NO stimulation of the soluble guanylyl
cyclase (sGC). The therapeutic effectiveness of GTN is
severely limited by the development of nitrate tolerance,
which is the loss of NO-dependent vasodilation after
exposure to GTN. More than a century after its first
description, the mechanism of nitrate tolerance remains a
mystery. Recently, much interest has focused on another
NO-dependent signal, S-nitrosylation, which could mod-
ulate vascular physiology and pathophysiology.
We recently discovered that sGC is S-nitrosylated in cells
following treatment with CSNO (S-nitrosocysteine) and
that S-nitrosylation correlates with a decrease in NO-sim-
ulated sGC activity. We demonstrated in vitro with semi-
purified sGC that S-nitrosylation causes directly desensiti-
zation (Sayed et al, submitted). We now show that S-
nitrosylation induces vascular tolerance in vivo: NO-
dependent vasorelaxation in the vascular system of ham-
ster's pouches was blunted following topical application
of CSNO. The cytosols of CSNO treated tissues contained
S-nitrosylated sGC and lost most of NO-stimulated sGC
activity. These results suggest that S-nitrosylation of sGC
leads to its desensitization, which in turn contributes to
NO tolerance.
We hypothesized that GTN could induce tolerance by
desensitization of sGC via S-nitrosylation. We demon-
strated that treatment of primary aortic smooth muscle
cells with GTN induces S-nitrosylation of endogenous
sGC together with its desensitization. We established that
desensitization and S-nitrosylation both reverse with pre-
treatment with N-acetyl-cysteine, which is a precursor of
glutathione synthesis and is used clinically to reverse tol-
erance. Finally, using our in vivo model, we established
that sGC of treated tissues that exhibited GTN-tolerance
was S-nitrosylated. Taken together these results suggest,
for the first time, that desensitization of sGC via S-
nitrosylation contributes to GTN-induced nitrate toler-
ance.
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